Korean pharma/CDMO, part of Dong-A Socio Group, making its own generic drugs plus contract-manufacturing oligonucleotide APIs.
Korean pharma/CDMO, part of Dong-A Socio Group, making its own generic drugs plus contract-manufacturing oligonucleotide APIs.
Is paid per batch or under supply agreements by drug developers for making oligonucleotides, short strands of genetic material used as drugs, so revenue depends on when customers' drugs move from trials to commercial supply. Its own branded generics are a smaller, more domestic line.
Moat: narrow (process know-how, customer qualification). One of few global-scale oligonucleotide API manufacturers, a specialized, hard-to-replicate process.
Headquarters: Seoul, South Korea · Founded: 1959 · Employees: 780
Size ST Pharm (237690.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.11B, the 224th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩70,200 on 18 Nov 2026.
Performance Over six months the shares fell 50.7%, against -9.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 26.3% over the last twelve months (peer median -1.5%); the operating margin is 17.8% (peer median 4.5%).
Valuation It trades at 27.8× forward earnings against a peer median of 20.2× (5th most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.8 points above its cost of capital (6.2% WACC).
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩402B | ₩332B | ₩274B | ₩285B | ₩249B |
| Revenue growth | — | +21% | -4% | +14% | — |
| Gross profit | ₩148B | ₩129B | ₩90.6B | ₩107B | ₩83.3B |
| EBITDA | ₩106B | ₩84.4B | ₩53.0B | ₩54.1B | ₩35.5B |
| Net income | ₩60.2B | ₩55.0B | ₩34.7B | ₩19.6B | ₩18.0B |
| Free cash flow | ₩65.7B | -₩29.6B | ₩30.2B | -₩41.6B | -₩53.0B |
| Capital expenditure | ₩31.1B | ₩47.3B | ₩83.2B | ₩43.4B | ₩60.7B |
| Total debt | ₩49.8B | ₩78.7B | ₩118B | ₩192B | ₩135B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 237690.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.9% | -2.0% | 2nd lowest of 21 |
| 6-month return | -50.7% | -9.7% | lowest of 20 |
| Distance from 52-week high | -59.2% | -30.2% | 3rd lowest of 21 |
| Revenue growth (TTM) | +26.3% | -1.5% | 7th highest of 18 |
| Operating margin | 17.8% | 4.5% | 3rd highest of 19 |
| Forward P/E | 27.8× | 20.2× | 5th most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 4.2% | 2.9% | 4th most demanding of 9 |
| Growth delivered (Del g) | +21.7% | +5.4% | highest of 9 |
| Hurdle (Req g minus delivered) | -17.6 pp | +4.8 pp | least demanding of 9 |
| ROIC minus cost of capital | +3.8 pp | -3.8 pp | 4th highest of 19 |
| EV / EBITDA | 13.2× | 14.9× | 3rd cheapest of 6 |
| Net debt / EBITDA | -0.8× | -1.7× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 27.8× | 4.2% | +21.7% |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 32.2× | 36.3% | +20.4% |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 18.1× | 4.9% | +11.3% |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 4.6× | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% | +4.2% |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 418.7× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | n/a | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 18.4× | 3.4% | -1.2% |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 14.5× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% | -9.0% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | n/a | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | n/a | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 60.4× | n/a | n/a |